Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company PIC

Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked

Fineline Cube Aug 27, 2026
Company PIC

HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%

Fineline Cube Aug 27, 2026
Company PIC

Junshi Biosciences Achieves First‑Ever Semiannual Profitability as Toripalimab Sales Surge 36%

Fineline Cube Aug 27, 2026
Company Drug PIC

FDA Approves Revolution Medicines’ Rasonque (daraxonrasib), an Oral Multi‑Selective RAS(ON) Inhibitor, for Metastatic Pancreatic Cancer

Fineline Cube Aug 27, 2026
Company Drug PIC

NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer

Fineline Cube Aug 26, 2026
Company PIC

Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked

Fineline Cube Aug 27, 2026
Company PIC

Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked

Fineline Cube Aug 27, 2026
Company PIC

HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%

Fineline Cube Aug 27, 2026
Company

WuXi Biologics CEO Outlines Growth Amid Global Challenges at J.P. Morgan Conference

Fineline Cube Jan 16, 2023

China-based WuXi Biologics (HKG: 2269) delivered a speech at the J.P. Morgan Healthcare Conference, where...

Company Drug

Hengrui’s Generic Cyclophosphamide Capsules Approved by China’s NMPA

Fineline Cube Jan 16, 2023

China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving marketing approval from the National Medical...

Company Deals

ReLive Biotechnologies Acquires Co.Don AG, Secures USD 36 Million for Expansion

Fineline Cube Jan 16, 2023

Tissue engineering and regenerative medicine start-up ReLive Biotechnologies Ltd has announced the full acquisition of...

Company Drug

Akeso’s Penpulimab Secures New Approval for Lung Cancer Indication

Fineline Cube Jan 16, 2023

China-based Akeso Biopharma (HKG: 9926) has announced receiving another indication approval from the National Medical...

Company Drug

Clover Biopharmaceuticals Plans COVID-19 Vaccine SCB-2019 Launch in China for 2023

Fineline Cube Jan 16, 2023

China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has provided updates on its plans for the commercialization...

Company Drug

Amoytop’s AK0706 Receives Clinical Trial Approval for Hepatitis B Treatment

Fineline Cube Jan 16, 2023

Xiamen-based Amoytop Biotech Co. Ltd has announced receiving clinical trial approval from China’s National Medical...

Company Deals

JHM Biopharma Raises RMB100 Million to Expand Protein Drug Pipeline

Fineline Cube Jan 16, 2023

Hangzhou-based protein drug developer JHM Biopharma has reportedly secured close to RMB100 million (USD14.9 million)...

Company Drug

Sino Biopharma’s PD-L1 Combo with Anlotinib Accepted for Review by China’s CDE

Fineline Cube Jan 16, 2023

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its New Drug Application (NDA) filing...

Company Deals

Meheco’s Genertec Partners with AstraZeneca for COVID-19 Antibody Evusheld in China

Fineline Cube Jan 16, 2023

China Meheco Group Co., Ltd (SHA: 600056) announced that its subsidiary Genertec Meheco has entered...

Company Drug

Guangzhou’s Overseas Pharma Wins China Clinical Trial Approval for OPL-038

Fineline Cube Jan 16, 2023

Guangzhou-based Overseas Pharmaceuticals, Ltd has secured clinical trial approval in China for its sustained and...

Company Deals

Eyougene Raises Hundreds of Millions in Series B Funding for Expansion

Fineline Cube Jan 13, 2023

Eyougene Co., Ltd, a digital Contract Development and Manufacturing Organization (CDMO) based in Shanghai, has...

Company Deals

LePure Bio Secures Hundreds of Millions in Series C Funding for Expansion

Fineline Cube Jan 13, 2023

Shanghai LePure Biotech Co., Ltd, a China-based biotechnology company, has reportedly raised “hundreds of millions”...

Company Deals

Shenzhen Keyto Fluid Control Secures Series C Funding for Expansion

Fineline Cube Jan 13, 2023

Shenzhen Keyto Fluid Control Co., Ltd, a China-based manufacturer of precision fluid control components, has...

Company Drug

Xinhua Pharma’s OAB-14 Receives NMPA Approval for Phase I Alzheimer’s Study

Fineline Cube Jan 13, 2023

China-based Shandong Xinhua Pharmaceutical Co., Ltd (SHE: 000756) has announced receiving approval from the National...

Company Deals

Cii Tech Secures Tens of Millions in Pre-Series A Funding for Mass Spectrometry

Fineline Cube Jan 13, 2023

China Innovation Instrument (Cii Tech), a life sciences instrument maker based in Ningbo, has reportedly...

Company Deals

TechnoDerma Raises Series A+ Funding to Advance Dermatology Pipeline

Fineline Cube Jan 13, 2023

TechnoDerma Medicines Inc., a Zhejiang-based developer of dermatology small molecules, has reportedly raised “tens of...

Company Drug

Konruns’ KC1036 Advances to Phase II Study for Lung Adenocarcinoma

Fineline Cube Jan 13, 2023

Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced receiving approval from the National Medical...

Company Drug

Harbour BioMed’s HBM1020 Receives FDA Approval for US Phase I Study

Fineline Cube Jan 13, 2023

Harbour BioMed (HKG: 2142), a global biotech company operating in the Netherlands, the United States,...

Company

Porton Pharma Solutions to Invest EUR 50 Million in Slovenia Bio-Industry Park

Fineline Cube Jan 13, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions is set to establish a...

Company Digital

ClouDr Partners with Shaanxi Pharmaceutical Firms for Integrated Healthcare Solutions

Fineline Cube Jan 13, 2023

Hangzhou Kang Ming Information Technology Co., Ltd (HKG: 9955), better known as “ClouDr,” has announced...

Posts pagination

1 … 620 621 622 … 713

Recent updates

  • Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked
  • HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%
  • CSPC’s PD-1/IL-15 Bispecific SYS6090 (JMT108) Granted FDA Fast Track for MSS/pMMR Metastatic Colorectal Cancer
  • Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3
  • Huadong Medicine’s ROR1 ADC HDM2005 Granted FDA Fast Track Designation — First Domestic ROR1 ADC to Achieve the Status
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company PIC

Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked

Company PIC

HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%

Company Drug

CSPC’s PD-1/IL-15 Bispecific SYS6090 (JMT108) Granted FDA Fast Track for MSS/pMMR Metastatic Colorectal Cancer

Company

Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.